-
Most Recent
Search Results
240 results for dgse
NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today
News that Australia has received its first shipment of Novavax’s Covid-19 vaccine has NVAX stock taking off nearly 9% in today’s trading.
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.
5 ETFs to Play Apple’s Big Rally
These five funds give you a big, low-cost dose of Apple stock exposure while also offering diversification across a number of other positions.
Trade of the Day: Micron Technology (MU)
A healthy dose of caution is always appropriate, which is why I continue to recommend short-term covered calls with a mix of long-term dividend names.
Europe, America Play Well Together — Thursday’s IP Market Recap
Stocks roared Thursday on a double dose of good news, from the ECB and on the U.S. jobs front. Also, Navistar and Men’s Wearhouse surged…
Developed World Boosters Offer Big Market for Eventual Novavax Vaccine
Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead.
Novavax Is Oversold, Time To Buy for Future Growth
NVAX stock seems oversold. Focus on low-income countries is likely to deliver revenue and cash flows from covid-19 vaccine sales in 2022.
Moderna Stock Looks Too Cheap After This Recent Dip
Investors who enjoyed a five-fold return this year are selling now but more upside approaches as Moderna ships vaccines worldwide.
Novavax Is Worth $165 Once Its Covid-19 Vaccine Is Ready
NVAX stock is set to move higher once its Covid-19 vaccine is ready. If its clinical trials succeed, NVAX stock is worth $165 per share,…
Big Catalysts Are Just Around the Corner for iBio Stock
Asset prices don’t go up in a straight line, even if the company shows promise. Use the dip in IBIO stock now to get in…
Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study
Minerva Neurosciences (NERV) is seeing NERV stock nosedive on Friday after announcing results from a recent schizophrenia study.
OCGN Stock: The Big COVAXIN News That Ocugen Bulls Should Watch
OCGN stock bulls should pay close attention to the latest news on the COVAXIN vaccine and on speculative social media chatter.
ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results
ArQule (ARQL) stock is skyrocketing more than 30% as the company’s blood cancer drug ARQ 531 has begun showing promise in its early going.
Bristol-Myers’ Near Term Rides on Blood Thinner Study
It’s likely sink-or-swim later this month when results are announced.
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.
Is BioNTech a Buy Ahead of Earnings?
Many biotech companies are working on COVID-19 vaccines, but I believe BioNTech stands to be one of the biggest winners in the months ahead.
Biden Vaccine Rollout Plan Assures Success for Moderna
Moderna stock investors should be glad to know that the government is ordering huge quantities of Covid-19 vaccines from just two companies.
Novavax Stock Is an Underdog You Should Bank On
The development a Covid-19 vaccine is no longer a race to the finish line, but there are still plenty of reasons to buy NVAX stock.
Don’t Count on OTC Lipitor as an Rx for Higher PFE Stock
PFE stock holders are looking forward to cholesterol reducer Lipitor becoming an OTC drug, but Pfizer shareholders may have a long and disappointing wait.
Zagfen Obesity Drug Trial Results Send ZFGN Soaring
Zagfen shares were flying high on Wednesday following positive results from a Phase III drug trial of its new obesity drug.
Novavax Stock Is on the Way with Ramp up in EUA Filings
NVAX has fallen sharply recently, but the time is ripe to buy this stock and take advantage of near-term catalysts like EUA filings.
Novavax Looks Like a Good Stock to Trade
For retail traders seeking short-term profits, NVAX stock is looking interesting once again. However, it’s not a good long-term investment.
Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness
The patent waiver matter will likely prove to be a “nonissue,” while NVAX stock has many upcoming, positive catalysts.
6 – 10 of 240 results
